Moffitt Cancer Center Administration includes the Research Executive Committee (REX), Scientific Leadership Committee (SLC), and Research Administration. REX establishes the overall scientific direction of the Center through strategic planning investment, evaluation, and nimble, coordinated activities that take advantage of unique opportunities or that address problems. Research Administration operationalizes and supports this vision. REX members include the Center Director and the six Associate Center Directors (ACDs) of Basic, Clinical, Population, and Translational Sciences; Education & Training; and Research Administration. This committee meets weekly for one and a half to two hours. This frequency ensures that activities related to recruitment, research development (including the Grant Review Committee, GRC), planning, space, academic affairs, and policy are rapidly addressed, while fostering a highly collaborative and integrated culture. The REX members are all highly productive scientists and leaders; collectively they have more than 110 years of Cancer Center leadership experience. SLC includes REX plus Program Leaders and Center of Excellence (transdisciplinary interest groups) Leaders. This group advises the Director and REX, with subcommittees for shared resources (Core Leadership Committee, CLC), member evaluation (Membership Committee, MC), clinical science (Clinical Research Action Committee, CRAC), and technology transfer/development (Innovation & Technology Committee, ITC). CCSG Research Administration is composed of 68 (only 2.6 FTE requested) staff members that support Moffitt's 142 Members, 698 other staff, and 13 shared resources. Reporting to the ACD of Research Administration, the administrative unit includes three Senior Directors, five Directors, four Managers, and their teams. Administration assists the Center Director in the ongoing research strategic planning and evaluation process; regular member and staff communications; faculty recruitment; shared resource oversight, including chargebacks, performance review, and user satisfaction; managing the $145 million annual budget, including philanthropic funds; awarding and monitoring more than $2 million in annual institutionally-supported developmental awards; managing and implementing MCC policies for 333,000-sf of dedicated research space; conducting the quarterly membership review and monitoring process; and arranging and documenting approximately 150 Center meetings and retreats per year. The current budget requests for Senior Leadership and Administration are $174,034 (9% of CCSG budget) and $153,888 (8% of CCSG budget), respectively. Collectively this represents less than 0.3% of the overall institutional research budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-21
Application #
9637338
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2019-02-01
Project End
2022-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
21
Fiscal Year
2019
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556
Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459
Poort, Hanneke; Meade, Cathy D; Knoop, Hans et al. (2018) Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients. Cancer Nurs 41:E28-E37
Pamnani, Shitaldas J; Sudenga, Staci L; Rollison, Dana E et al. (2018) Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study. J Infect Dis 218:1219-1227
Dai, Juncheng; Li, Zhihua; Amos, Christopher I et al. (2018) Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. Carcinogenesis :
Cherezov, Dmitry; Hawkins, Samuel H; Goldgof, Dmitry B et al. (2018) Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial. Cancer Med 7:6340-6356

Showing the most recent 10 out of 1254 publications